EICHOR
● Not Yet Recruiting
VALSE: Integration of Neuromodulation and Exoskeleton Systems for Mobility in Individuals With Chronic Spinal Cord Injury
Condition: Spinal Cord Injury · Sponsor: Ecole Polytechnique Fédérale de Lausanne
About this study
The purpose of this clinical study is to evaluate the preliminary safety and feasibility of using the VALSE system, which combines spinal cord stimulation with the TWIICE robotic exoskeleton, to support motor recovery and reduce reliance on laboratory-based equipment during rehabilitation in participants with traumatic spinal cord injury. The TWIICE exoskeleton is integrated through the NR system, a platform developed by EPFL. The goal is to assess the clinical safety and practical application of this combined neuroprosthetic approach in a small number of participants, in order to guide future refinements of the device and protocol, support the development of scalable interventions integrating spinal stimulation with robotic assistance, and inform strategies for delivering rehabilitation in more accessible, real-world environments.
This description comes directly from the study's public registry record.
Talk to the study team
Jocelyne Bloch, Prof. · +41 79 556 29 51 · jocelyne.bloch@chuv.ch
Henri Lorach, PhD · +41 77 495 50 48 · henri.lorach@epfl.ch
Always discuss trial participation with your own doctor first.
Locations (1)
| Centre Hospitalier Universitaire Vaudois (CHUV) | Lausanne, Canton of Vaud, Switzerland | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07745686